Aligos Therapeutics Inc. (ALGS): Price and Financial Metrics
GET POWR RATINGS... FREE!
ALGS Stock Price Chart Interactive Chart >
ALGS Price/Volume Stats
|Current price||$1.94||52-week high||$3.32|
|Prev. close||$1.87||52-week low||$0.84|
|Day high||$1.98||Avg. volume||905,110|
|50-day MA||$1.24||Dividend yield||N/A|
|200-day MA||$1.24||Market Cap||83.06M|
Aligos Therapeutics Inc. (ALGS) Company Bio
Aligos Therapeutics, Inc. develops targeted, curative therapies for hepatologic diseases and viral infections. It engages in building a pipeline of drug candidates which targets multiple clinically validated mechanisms of action and are designed to achieve functional cure for CHB and become transformative treatment options for COVID-19 and NASH. The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA.
Most Popular Stories View All
ALGS Latest News Stream
|Loading, please wait...|
ALGS Latest Social Stream
View Full ALGS Social Stream
Latest ALGS News From Around the Web
Below are the latest news stories about ALIGOS THERAPEUTICS INC that investors may wish to consider to help them evaluate ALGS as an investment opportunity.
Aligos Therapeutics (NASDAQ:ALGS) adds US$18m to market cap in the past 7 days, though investors from a year ago are still down 34%
Aligos Therapeutics, Inc. ( NASDAQ:ALGS ) shareholders will doubtless be very grateful to see the share price up 126...
Aligos Therapeutics on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009
– Final cohort of Phase 1 study projected to be complete in H1 2023 – – Phase 2-enabling GLP toxicology studies projected to be complete in H2 2023 – – Clinical update on all pipeline programs to be presented at the 2023 J.P. Morgan Healthcare Conference on January 12 at 10:30 a.m. PT – SOUTH SAN FRANCISCO, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medica
Aligos Therapeutics Initiates Dosing with its Small Interfering RNA (siRNA) Drug Candidate, ALG-125755, in Subjects with Chronic Hepatitis B (CHB)
Single and multiple ascending doses to be evaluated in CHB subjects throughout 2023SOUTH SAN FRANCISCO, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, reported today that dosing with ALG-125755, a small interfering RNA (siRNA) targeting the production of hepatitis B surface antigen (HBsAg), was initiated in subjects w
Aligos Therapeutics Presents Nonclinical Data for its Coronavirus Therapeutic Program at the 2022 Respi DART Meeting
Coronavirus protease inhibitor, ALG-097558, has demonstrated antiviral activity in vivo and promising pan-coronavirus activity in vitroFirst-in-human studies anticipated to begin in H1 2023 SOUTH SAN FRANCISCO, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company presented the progress to da
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
ALGS Price Returns